Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;
Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
/Tesla%20charging%20station%20black%20background%20by%20Blomst%20via%20Pixabay.jpg)